Close
Solutions
Online Inquiry
Global Services

In Vivo Generation of CAR-T Cells in Human CD4+ Lymphocytes

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

In recent years, it has been proved that the use of T cells with chimeric antigen receptors (CAR) for cellular immunotherapy is an effective therapy for the treatment of B cell hematological malignancies. T cells modified with CD19-specific chimeric antigen receptors (CARs) can bring significant clinical benefits to leukemia patients, but pose a challenge to production because CAR-T cells are personalized cell therapy products that require large amounts and time-consuming manufacturing process.

As the leading cell therapeutics biotech company that provides CAR-T cell therapy related services, Creative Biolabs masters the most advanced technology and has a very rich extensive experience and thus, can offer the best CAR treatment products. Our team is committed to exploring the feasibility of using lentiviral methods to target CAR genes to CD4 subtypes. We demonstrated the in vivo generation of CAR-T cells selectively produced in CD4+ cells by using CD4-targeted LV (CD4-LV). This innovated description of in vivo-generated CD4+ CAR-T cells supports their importance for cellular therapy.

Rational Design

The surface markers of human lymphocytes have received special attention. As the main effector cells, CD4 T cells are known for their auxiliary functions and enhance the activity of CD8 T cells through the production of cytokines, thereby inherently arousing cytolytic activity. There are also reports that CD4 T cells have direct cytotoxic activity in mediating anti-tumor activity.

Our research team has explored the feasibility of using lentiviral methods to target CAR genes to CD4 subtypes. In this study, we demonstrated the in vivo generation of CD19-CAR T cells selectively in CD4+ cells by using CD4-targeted LV (CD4-LV). The results of the study showed that humanized NSG mice administered CD4-LV showed rapid kinetic CAR-T cell production in humans. These CD4+ CAR-T cells can greatly reduce or even eliminate CD19+ cells. The data shows that CD4+ CAR-T cells are highly correlated with the production of CAR-T cells in vivo.

Schematic illustration of CAR-T cells generation in vivo.

Fig.1 Schematic illustration of CAR-T cells generation in vivo.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.